Smart for Life develops gluten-free diet cookie
BOCA RATON, Fla. Weight-management products company Smart for Life has developed a diet cookie for those with gluten sensitivity.
The gluten-free banana chocolate chip granola square has no preservatives and is made with many organic ingredients and a balanced protein formula with healthy fats and carbohydrate ratios. As with all Smart for Life products, this gluten-free line also effectively suppresses the appetite, the company said.
"The gluten-free market is growing, but unfortunately, a lot of gluten-free products do not taste that great. We have been able to create a delicious taste profile that people will be amazed to know happens to be gluten-free," said Richard Kayne, Smart for Life COO.
PharmaLink gets orphan drug designation for Nefecon
STOCKHOLM The Food and Drug Administration has given orphan drug designation to a treatment for a rare kidney disease under mid-stage clinical development by privately owned Swedish drug maker PharmaLink, the company said.
The FDA granted the designation to Nefecon (PL-56), a treatment for IgA nephropathy, also known as Berger’s disease, a disorder that leads to end-stage kidney disease. The FDA gives orphan drug designation to incentivize development of treatments for rare and serious disorders.
“Today’s news marks a significant milestone for PharmaLink and increases the commercial value of Nefecon as it moves toward the marketplace,” PharmaLink managing director Johan Haggblad said. “We believe this product candidate has great potential in treating IgA nephropathy.”
Medco: Poor adherence may cause lack of response to medication
BOSTON When a patient isn’t showing a response to a medication, a common tactic the doctor might use is to increase the dosage. According to a new study, however, the ineffectiveness might be happening because the patient isn’t properly taking the medication.
The Medco Research Institute, the research arm of pharmacy benefit manager Medco Health Solutions, found that nearly one-third of patients given increased dosages of antidepressants were not regularly taking their original prescriptions. Data from the study recently were presented at the American Psychiatric Association’s 62nd Institute on Psychiatric Services in Boston.
Medco said the study showed doctors should monitor a patient’s adherence to their antidepressants before raising the dosage because poor adherence may contribute to disease relapse, thus leading to unnecessary dosage increases.
“A physician usually increases a dose when a patient is not responding to the current dosage,” Medco Neuroscience Therapeutic Resource Center national practice leader and lead study author David Muzina said. “But the analysis shows that the reason the dose may not be effective is that many patients are not taking their antidepressants as directed.”